Table 1.
Patient characteristics
| Variable | Category | Pancreas N = 46 | Esophagus N = 60 | Gastric N = 25 | UGI cancer N = 131 |
|---|---|---|---|---|---|
| WHO performance status | 0/1 | 28 (60.9%) | 39 (65.0%) | 16 (64.0%) | 83 (63.4%) |
| 2 | 12 (26.1%) | 16 (26.7%) | 6 (24.0%) | 34 (26.0%) | |
| 3 | 5 (10.9%) | 4 (6.7%) | 3 (12.0%) | 12 (9.2%) | |
| Unknown | 1 (2.2%) | 1 (1.7%) | 0 (0.0%) | 2 (1.5%) | |
| Tumor grade | 1 | 2 (4.3%) | 1 (1.7%) | 0 (0.0%) | 3 (2.3%) |
| 2 | 12 (26.1%) | 18 (30.0%) | 6 (24.0%) | 36 (27.5%) | |
| 3 | 16 (34.8%) | 40 (66.7%) | 17 (68.0%) | 73 (55.7%) | |
| Not assessablea | 16 (34.8%) | 1 (1.7%) | 2 (8.0%) | 19 (14.5%) | |
| AJCC stage 2010 | II/III | 11 (23.9%) | 25 (41.7%) | 8 (32.0%) | 44 (33.6%) |
| IV | 33 (71.7%) | 34 (56.7%) | 17 (68.0%) | 84 (64.1%) | |
| Not assessableb | 2 (4.3%) | 1 (1.7%) | 0 (0.0%) | 3 (2.3%) | |
| Weight loss | None | 17 (37.0%) | 21 (35.0%) | 5 (20.0%) | 43 (32.8%) |
| ≤10% | 12 (26.1%) | 20 (33.3%) | 4 (16.0%) | 36 (27.5%) | |
| >10% | 16 (34.8%) | 17 (28.3%) | 14 (56.0%) | 47 (35.9%) | |
| Unknown | 1 (2.2%) | 2 (3.3%) | 2 (8.0%) | 5 (3.8%) | |
| Smoking status | Current | 7 (15.2%) | 12 (20.0%) | 5 (20.0%) | 24 (18.3%) |
| Ex ≤ 12 months | 2 (4.3%) | 3 (5.0%) | 1 (4.0%) | 6 (4.6%) | |
| Ex > 12 months | 17 (37.0%) | 18 (30.0%) | 10 (40.0%) | 45 (34.4%) | |
| Never | 15 (32.6%) | 22 (36.7%) | 6 (24.0%) | 43 (32.8%) | |
| Unknown | 5 (10.9%) | 5 (8.3%) | 3 (12.0%) | 13 (9.9%) | |
| Prior treatment status | None | 32 (69.6%) | 38 (63.3%) | 19 (76.0%) | 89 (67.9%) |
| Adjuvant/Neoadjuvant chemotherapy | 3 (6.5%) | 7 (11.7%) | 1 (4.0%) | 11 (8.4%) | |
| Palliative chemotherapy | 11 (23.9%) | 15 (25.0%) | 5 (20.0%) | 31 (23.7%) | |
| Subsequent treatment status | None | 6 (13.0%) | 13 (21.7%) | 6 (24.0%) | 25 (19.1%) |
| Chemotherapy | 21 (45.7%) | 28 (46.7%) | 19 (76.0%) | 68 (51.9%) | |
| Chemoradiation | 0 (0.0%) | 8 (13.3%) | 0 (0.0%) | 8 (6.1%) | |
| Biological agent | 0 (0.0%) | 1 (1.7%) | 0 (0.0%) | 1 (0.8%) | |
| Chemotherapy and biological agent | 19 (41.3%) | 7 (11.7%) | 0 (0.0%) | 26 (19.8%) | |
| Randomized controlled trial | 0 (0.0%) | 3 (5.0%) | 0 (0.0%) | 3 (2.3%) | |
| Survival status | Alive | 9 (19.6%) | 23 (38.3%) | 8 (32.0%) | 40 (30.5%) |
| Dead | 37 (80.4%) | 37 (61.7%) | 17 (68.0%) | 91 (69.5%) | |
| Unknown | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
aTumor grade not assessable due to insufficient tissue (e.g., fine-needle aspirate, cytological diagnosis)
bStage not assessable with tumor recurrence following prior resection